MK-4002, a B-cell maturation antigen-targeting T-cell engager, in relapsed or refractory multiple myeloma: a first-in-human, open-label, phase 1 study.
BACKGROUND The optimal treatment strategy for relapsed or refractory multiple myeloma remains unclear. This first-in-human study aimed to evaluate the safety, preliminary activity, and pharmacokinetics of the trispecific B-cell maturation antigen-targeting T-cell engager MK-4002 in relapsed or refractory multiple myelo...